130 related articles for article (PubMed ID: 16969131)
21. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
22. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
23. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.
Bentle MS; Reinicke KE; Bey EA; Spitz DR; Boothman DA
J Biol Chem; 2006 Nov; 281(44):33684-96. PubMed ID: 16920718
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.
Fong S; Shoemaker M; Cadaoas J; Lo A; Liao W; Tagliaferri M; Cohen I; Shtivelman E
Cancer Biol Ther; 2008 Apr; 7(4):577-86. PubMed ID: 18305410
[TBL] [Abstract][Full Text] [Related]
25. beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Huang L; Pardee AB
Mol Med; 1999 Nov; 5(11):711-20. PubMed ID: 10656873
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
28. Beta-lapachone, a quinone isolated from Tabebuia avellanedae, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase.
Woo HJ; Park KY; Rhu CH; Lee WH; Choi BT; Kim GY; Park YM; Choi YH
J Med Food; 2006; 9(2):161-8. PubMed ID: 16822200
[TBL] [Abstract][Full Text] [Related]
29. Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.
He T; Banach-Latapy A; Vernis L; Dardalhon M; Chanet R; Huang ME
Carcinogenesis; 2013 Apr; 34(4):760-9. PubMed ID: 23239746
[TBL] [Abstract][Full Text] [Related]
30. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction.
Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2011 Aug; 301(2):F450-9. PubMed ID: 21613422
[TBL] [Abstract][Full Text] [Related]
31. Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model.
Seoane S; Díaz-Rodríguez P; Sendon-Lago J; Gallego R; Pérez-Fernández R; Landin M
Eur J Pharm Biopharm; 2013 Aug; 84(3):497-504. PubMed ID: 23333901
[TBL] [Abstract][Full Text] [Related]
32. Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage.
Jelezcova E; Trivedi RN; Wang XH; Tang JB; Brown AR; Goellner EM; Schamus S; Fornsaglio JL; Sobol RW
Mutat Res; 2010 Apr; 686(1-2):57-67. PubMed ID: 20096707
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
34. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
Brenner JC; Ateeq B; Li Y; Yocum AK; Cao Q; Asangani IA; Patel S; Wang X; Liang H; Yu J; Palanisamy N; Siddiqui J; Yan W; Cao X; Mehra R; Sabolch A; Basrur V; Lonigro RJ; Yang J; Tomlins SA; Maher CA; Elenitoba-Johnson KS; Hussain M; Navone NM; Pienta KJ; Varambally S; Feng FY; Chinnaiyan AM
Cancer Cell; 2011 May; 19(5):664-78. PubMed ID: 21575865
[TBL] [Abstract][Full Text] [Related]
36. Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1).
Choi YH; Kang HS; Yoo MA
J Biochem Mol Biol; 2003 Mar; 36(2):223-9. PubMed ID: 12689523
[TBL] [Abstract][Full Text] [Related]
37. Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation.
Kumari A; Iwasaki T; Pyndiah S; Cassimere EK; Palani CD; Sakamuro D
Cell Death Differ; 2015 Feb; 22(2):311-22. PubMed ID: 25257171
[TBL] [Abstract][Full Text] [Related]
38. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
39. Cancer therapy with beta-lapachone.
Pardee AB; Li YZ; Li CJ
Curr Cancer Drug Targets; 2002 Sep; 2(3):227-42. PubMed ID: 12188909
[TBL] [Abstract][Full Text] [Related]
40. Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.
Brunyanszki A; Olah G; Coletta C; Szczesny B; Szabo C
Mol Pharmacol; 2014 Oct; 86(4):450-62. PubMed ID: 25069723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
